2022 World Conference on Lung Cancer (ePosters)-EP05.01-030. CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany

Pdf Summary

The CLINICAL RESEARCH PLATFORM INTO MOLECULAR TESTING, TREATMENT AND OUTCOME OF NON-SMALL CELL LUNG CARCINOMA PATIENTS (CRISP) is a study conducted in Germany to understand the treatment reality of patients with non-small cell lung cancer (NSCLC). The study includes patients diagnosed with stage I, II, and III NSCLC, with a focus on patients in early stages. The aim of the study is to collect and analyze data on patient and tumor characteristics, treatment strategies, outcomes, and patient-reported outcomes.<br /><br />As of June 2021, the study has recruited over 1500 patients from over 100 sites in Germany. The majority of the patients have been diagnosed with stage III NSCLC, with a smaller percentage diagnosed with stage II and only 1% diagnosed with stage I. The most common tumor histologies observed were adenocarcinoma and squamous cell carcinoma.<br /><br />The treatment strategies for patients varied based on their clinical stage. For patients with stage II tumors, surgery followed by adjuvant chemotherapy was the most common treatment strategy. For patients with stage IIIA tumors, surgery followed by adjuvant chemotherapy or definitive radiochemotherapy was commonly utilized. For patients with stage IIIB/C tumors, definitive radiochemotherapy was the most frequent treatment strategy.<br /><br />Biomarker testing, specifically testing for PD-L1 expression, was conducted in 60% of the tumors. Among the non-resectable stage III tumors treated with radiochemotherapy, 80% were tested for PD-L1 expression. Approximately 49% of all patients and 61% of tested patients had positive PD-L1 expression. Out of the durvalumab-eligible patients, 44 received consolidation therapy with durvalumab.<br /><br />The study also looked at outcomes such as relapse-free survival (RFS), progression-free survival, and overall survival (OS). The 2-year RFS rate was 76.9% for stage II tumors and 51.5% for stage IIIA tumors. The 2-year OS rate was 90.0% for stage II tumors and 79.3% for stage IIIA tumors. For patients treated with radiochemotherapy, the median progression-free survival was 10.4 months for stage IIIA tumors and 9.2 months for stage IIIB/C tumors. The median overall survival was 21.5 months for stage IIIA tumors and 22.9 months for stage IIIB/C tumors.<br /><br />In conclusion, the CRISP study provides real-life data on the treatment and outcomes of patients with NSCLC in Germany. The study includes patients in early stages and covers various treatment settings. The data collected will help further understand the current treatment reality and outcomes of NSCLC patients.

Asset Subtitle

Wilfried Ernst Erich Eberhardt

Meta Tag

Speaker Wilfried Ernst Erich Eberhardt

Topic Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

Keywords

clinical research platform

molecular testing

treatment

outcome

non-small cell lung carcinoma

patients

Germany

adenocarcinoma

squamous cell carcinoma

biomarker testing